Diabetic Nephropathy

Textbook of Diabetes: Fourth Edition

Volumn , Issue , 2010, Pages 599-614

  Marshall, Sally M ^a   Flyvbjerg, Allan ^b  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Association of diabetic nephropathy with other complications of diabetes; Cardiovascular risk: smoking, lipids, aspirin; End stage renal disease (ESRD); Excluding other treatable causes of kidney disease; Management of chronic kidney disease stage 3 or poorer; Management of diabetic kidney disease; Prevention of kidney disease; Renal replacement therapy (RRT); Risk factors for diabetic nephropathy; Testing for kidney disease in diabetes

Indexed keywords

EID: 84878213082     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781444324808.ch37     Document Type: Chapter

References (167)

1. 1 US Renal Data System, USRDS. Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2008.
2. Van Dijk PC, Jager KJ, Stengel B, Gronhagen-Riska C, Feest TG, Briggs JD. Renal replacement therapy for diabetic end-stage renal disease: data from 10 registries in Europe (1991-2000). Kidney Int 2005; 67: 1489-1499.
3. Stewart JH, McCredie MR, Williams SM, Jager KJ, Trpeski L, McDonald SP; ESRD Incidence Study Group. Trends in incidence of treated end-stage renal disease, overall and by primary renal disease, in persons aged 20-64 years in Europe, Canada and the Asia-Pacific region, 1998-2002. Nephrology 2007; 12: 520-527.
4. Stewart JH, McCredie MR, Williams SM; ESRD Incidence Study Group. Divergent trends in the incidence of end-stage renal disease due to type 1 and type 2 diabetes in Europe, Canada and Australia during 1998-2002. Diabet Med 2006; 23: 1364-1369.
5. Levey AS, Coresh J, Balk E, Kausz AT, Levin A, Steffes MW, et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med 2003; 139: 137-147.
6. Magee GM, Bilous RW, Cardwell CR, Hunter SJ, Kee F, Fogarty DG. Is hyperfiltration associated with the future risk of developing diabetic nephropathy? A meta-analysis. Diabetologia 2009; 52: 691-697.
7. Microalbuminuria Collaborative Study Group. Predictors of the development of microalbuminuria in patients with type 1 diabetes mellitus: a seven year prospective study. Diabet Med 1999; 16: 918-925.
8. Chaturvedi N, Bandinelli S, Mangili R, Penno G, Rottiers RE, Fuller JH. Microalbuminuria in type 1 diabetes: rates, risk factors and glycemic threshold. Kidney Int 2001; 60: 219-227.
9. Mackin P, MacLeod JM, New J, Marshall SM. Renal function in long-duration type diabetes. Diabetes Care 1996; 19: 249-251.
10. Orchard TJ, Dorman JS, Maser RE, Becker DJ, Drash AL, Ellis D, et al. Prevalence of complications in IDDM by sex and duration. Diabetes 1990; 39: 1116-1124.
11. Warram JH, Gearin G, Laffel L, Krolewski AS. Effect of duration of type 1 diabetes on the prevalence of stages of diabetic nephropathy defined by urinary albumin/creatinine ratio. J Am Soc Nephrol 1996; 7: 930-937.
12. Raile K, Galler A, Hofer S, Herbst A, Dunstheimer D, Busch P, et al. Diabetic nephropathy in 2 7805 children, adolescents and adults with type 1 diabetes: effect of diabetes duration, A1C, hypertension, dyslipidemia, diabetes onset and sex. Diabetes Care 2007; 30: 2523-2528.
13. Diabetes Control and Complications Trial (DCCT) Research Group. Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. Kidney Int 1995; 47: 1703-1720.
14. Microalbuminuria Collaborative Study Group UK. Intensive therapy and progression to clinical albuminuria in patients with insulin dependent diabetes mellitus and microalbuminuria. Br Med J 1995; 311: 973-977.
15. Giorgino F, Laviola L, Cavallo Perin P, Solnica B, Fuller J, Chaturvedi N. Factors associated with progression to macroalbuminuria in microalbuminuric type 1 diabetic patients: the EURODIAB prospective Complications Study. Diabetologia 2004; 47: 1020-1028.
16. Perkins BA, Ficociello LH, Silva KH, Finkelstein DM, Warram JH, Krolewski AS. Regression of microalbuminuria in type 1 diabetes. N Engl J Med 2003; 348: 2285-2293.
17. Nordwall M, Bojestig M, Arnqvist HJ, Ludvigsson J. Declining incidence of severe retinopathy and persisting decrease of nephropathy in an unselected population of type 1 diabetes: the Linkoping Diabetes Complications Study. Diabetologia 2004; 46: 1266-1272.
18. Hovind P, Tarnow L, Rossing K, Rossing P, Eising S, Larsen N, et al. Decreasing incidence of severe diabetic microangiopathy in type 1 diabetes. Diabetes Care 2003; 26: 1258-1264.
19. Pambianco G, Costacou T, Ellis D, Becker DJ Klein R, Orchard TJ. The 30-year natural history of type 1 diabetes complications: the Pittsburgh Epidemiology of Diabetes Complications Study experience. Diabetes 2006; 55: 1463-1469.
20. Costacou T, Ellis D, Fried L, Orchard TJ. Sequence of progression of albuminuria and decreased GFR in persons with type 1 diabetes: a cohort study. Am J Kidney Dis 2007; 50: 721-732.
21. Svensson M, Nyström L, Schon S, Dahlquist G. Age at onset of childhood-onset type 1 diabetes and the development of end-stage renal disease: a nationwide population-based study. Diabetes Care 2006; 29: 538-542.
22. Sørensen VR, Mathiesen ER, Watt T, Bjorner JB, Andersen MV, Feldt-Rasmussen B. Diabetic patients treated with dialysis: complications and quality of life. Diabetologia 2007; 50: 2254-2262.
23. Astrup AS, Tarnow L, Rossing P, Pietraszek L, Riis Hansen P, Parving HH. Improved prognosis in type 1 diabetic patients with nephropathy: a prospective follow-up study. Kidney Int 2005; 68: 1250-1257.
24. Schmitz A, Hvid Hansen H, Christensen T. Kidney function in newly diagnosed type 2 (non-insulin-dependent) diabetes before and during treatment. Diabetologia 1989; 32: 434-439.
25. Patrick AW, Leslie PJ, Clarke BF, Frier BM. The natural history and associations of microalbuminuria in type 2 diabetes during the first year after diagnosis. Diabet Med 1990; 7: 902-908.
26. Nelson RG, Meyer TN, Myers BD, Bennett PH. Course of renal disease in Pima Indians with NIDDM. Kidney Int 1997; 52 (Suppl. 63): 45-48.
27. Vora JP, Dolben J, Deane JD, Thomas D, Williams JD, Owens DR, et al. Renal haemodynamics in newly presenting non-insulin dependent diabetes mellitus. Kidney Int 1992; 41: 829-835.
28. Vora JP, Dolben J, Williams JD, Peters JR, Owens DR. Impact of initial treatment on renal function in newly-diagnosed type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 1993; 36: 734-740.
29. Vedel P, Obel J, Nielsen FS, Bang LE, Svendsen TL, Pedersen OB, et al. Glomerular hyperfiltration in microalbuminuric NIDDM patients. Diabetologia 1996; 39: 1584-1589.
30. Marshall SM, Alberti KGMM. Comparison of the prevalence and associated features of abnormal albumin excretion in insulin dependent and non-insulin-dependent diabetes. Q J Med 1989;70: 61-71.
31. Allawi J, Rao PV, Gilbert P, Scott G, Jarrett RJ, Keen H, et al. Microalbuminuria in non-insulin-dependent diabetes: its prevalence in Indian compared with Europid patients. Br Med J 1988; 296: 462-464.
32. Gall MA, Rossing P, Skøtt P, Damsbo P, Vaag A, Bech K, et al. Prevalence of micro-and macroalbuminuria, arterial hypertension, retinopathy and large vessel disease in European type II (non-insulin-dependent) diabetic patients. Diabetologia 1991; 34: 655-661.
33. Collins VR, Dowse GK, Finch CF, Zimmet PZ, Linnane AW. Prevalence and risk factors for micro and macroalbuminuria in diabetic subjects and entire population of Nauru. Diabetes 1989; 38: 1602-1610.
34. Damsgaard EM, Mogensen CE. Microalbuminuria in elderly hyperglycaemic patients and controls. Diabet Med 1986; 3: 430-435.
35. Nelson RG, Knowler WC, Pettitt DJ, Hanson RL, Bennett PH. Incidence and determinants of elevated urinary albumin excretion in Pima Indians with NIDDM. Diabetes Care 1995; 18: 182-187.
36. Unnikrashnan RI, Rema M, Pradeepa R, Deepa M, Shanthirani CS, Deepa R, et al. Prevalence and risk factors of diabetic nephropathy in an urban South Indian population: the Chennai Urban Rural Epidemiology Study (CURES 45). Diabetes Care 2007; 30: 2019-2024.
37. Dasmahapatra A, Bale A, Raghuwanshi MP, Reddi A, Byrne W, Suarez S, et al. Incipient and overt nephropathy in African Americans with NIDDM. Diabetes Care 1994; 17: 297-304.
38. Gall MA, Hougaard P, Borch-Johnsen K, Parving H-H. Risk factors for development of incipient and overt diabetic nephropathy in patients with non-insulin dependent diabetes mellitus. Br Med J 1997; 314: 783-788.
39. Ravid M, Brosh D, Ravid-Safran D, Levy Z, Rachmani R. Main risk factors for nephropathy in type 2 diabetes mellitus are plasma cholesterol levels, mean blood pressure and hyperglycemia. Arch Intern Med 1998; 158: 998-1004.
40. Forsblom CM, Groop PH, Ekstrand A, Totterman KJ, Sane T, Saloranta C, et al. Predictors of progression from normoalbuminuria to microalbuminuria in NIDDM. Diabetes Care 1998; 21: 1932-1938.
41. Ruggenenti P, Fassi A, Ilieva AP, Bruno S, Iliev IP, Brusegan V, et al: Bergamo Nephrologic Diabetes Complications Trial (BENEDICT) Investigators. Preventing microalbuminuria in type 2 diabetes. N Engl J Med 2004; 351: 1941-1951.
42. Schmitz A, Væth M, Mogensen CE. Systolic blood pressure relates to the rate of progression of albuminuria in NIDDM. Diabetologia 1994; 37: 1251-1258.
43. Ravid M, Lang R, Rachmani R, Lishner M. Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus: a 7-year follow-up study. Arch Intern Med 1996; 156: 286-289.
44. Parving HH, Lehnert H, Br øchner-Mortensen J, Gomis R, Andersen S, Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870-878.
45. Hasslacher C, Ritz E, Wahl P, Michael C. Similar risks of nephropathy in patients with type I or type II diabetes mellitus. Nephrol Dial Transplant 1989; 4: 859-863.
46. Nelson RG, Morgenstern H, Bennett PH. An epidemic of proteinuria in Pima Indians with type 2 diabetes. Kidney Int 1998; 54: 2081-2088.
47. Pavkov ME, Knowler WC, Bennett PH, Looker HC, Krakoff J, Nelson RG. Increasing incidence of proteinuria and declining incidence of end-stage renal disease in diabetic Pima Indians. Kidney Int 2006; 70: 1840-1846.
48. Myers BD, Nelson RG, Tan M, Beck GJ, Bennett PH, Knowler WC, et al. Progression of overt nephropathy in non-insulin-dependent diabetes. Kidney Int 1995; 47: 1781-1789.
49. Earle KA, Porter KK, Ostberg J, Yudkin JS. Variation in the progression of diabetic nephropathy according to racial origin. Nephrol Dial Transplant 2001; 16: 286-290.
50. Roderick PJ, Jones J, Raleigh VS, McGeown M, Mallick N. Population need for renal replacement therapy in Thames regions: ethnic dimension. Br Med J 1994; 309: 1111-1114.
51. Cowie CC, Port FK, Wolfe RA, Savage PJ, Moll PP, Hawthorne VM. Disparities in incidence of diabetic end-stage renal disease according to race and type of diabetes. N Engl J Med 1989; 321: 1074-1079.
52. Hebet LA, Kusek JW, Greene T, Agodoa LY, Jones CA, Levey AS, et al. Effects of blood pressure control on progression of renal disease in Blacks and Whites: Modification of Diet in Renal Disease Study Group. Hypertension 1997; 30: 428-435.
53. Retnakaran R, Cull CA, Thorne KI, Adler AI, Holman RR; UK Prospective Diabetes Study Group. Risk factors for renal dysfunction in type 2 diabetes: UKPDS 74. Diabetes 2006; 55: 1832-1839.
54. Fioretto P, Mauer M, Brocco E, Velussi M, Frigato F, Muollo B, et al. Patterns of renal injury in NIDDM patients with microalbuminuria. Diabetologia 1996; 39: 1569-1576.
55. Christensen PK, Larsen S, Horn T, Olsen S, Parving HH. Causes of albuminuria in patients with type 2 diabetes without diabetic retinopathy. Kidney Int 2000; 58: 1719-1731.
56. Ross WR, MaGill JB. Epidemiology of obesity and chronic kidney disease. A dv Chronic Kidney Dis 2006; 1 3: 325-335.
57. Kramer CK, Leitao CB, Canani LH, Gross JL. Impact of white coat hypertension on microvascular complications in type 2 diabetes. Diabetes Care 2008; 31: 2233-2237.
58. Dost A, Klinkert C, Kapellen T, Lemmer A, Naeke A, Grabert M, et al. Arterial hypertension determined by ambulatory blood pressure profiles: contribution to microalbuminuria risk in a multicenter investigation in 2105 children and adolescents with type 1 diabetes. Diabetes Care 2008; 31: 720-725.
59. Thomas MC, Rosengard-Barlund M, Mills V, Ronnback M, Thomas S, Forsblom C, et al. Serum lipids and the progression of nephropathy in type 1 diabetes. Diabetes Care 2006; 29: 317-322.
60. Tolonen N, Forsblom C, Thorn L, Waden J, Rosengard-Barlund M, Saraheimo M, et al. Relationship between lipid profiles and kidney function in patients with type 1 diabetes. Diabetologia 2008; 51: 12-20.
61. Xu J, Lee ET, Devereux RB, Umans JG, Bella JN, Shara NM, et al. A longitudinal study of risk factors for incident albuminuria in diabetic American Indians: the Strong Heart Study. Am J Kidney Dis 2008; 51: 415-424.
62. Thorn LM, Forsblom C, Fagerudd J, Thomas MC, Pettersson-Fernholm K, Saraheimo M, et al. Metabolic syndrome in type 1 diabetes: association with diabetic nephropathy and glycemic control (the FinnDiane study). Diabetes Care 2005; 28: 2019-2024.
63. Kilpatrick ES, Rigby AS, Atkin SL. Insulin resistance, the metabolic syndrome, and complication risk in type 1 diabetes: "double diabetes" in the Diabetes Control and Complications Diabetes. Diabetes Care 2007; 30: 707-712.
64. Costa LA, Canani LH, Lisboa HR, Tres GS, Gross JL. Aggregation of features of the metabolic syndrome is associated with increased prevalence of chronic complications in type 2 diabetes. Diabet Med 2004; 21: 252-253.
65. Bonadonna RC, Cucinotta D, Fedele D, Riccardi G, Tiengo A; Metascreen Writing Committee. The metabolic syndrome is a risk indicator of microvascular and macrovascular complications in diabetes: results from Metascreen, a multicenter diabetes clinic-based survey. Diabetes Care 2006; 29: 2701-2710.
66. Murussi M, Campagnolo N, Beck MO, Gross JL, Silveiro SP. High-normal levels of albuminuria predict the development of micro-and macroalbuminuria and increased mortality in Brazilian type 2 diabetic patients: an 8-year follow-up study. Diabet Med 2007; 24: 1136-1142.
67. De Zeeuw D, Ramjit D, Zhang Z, Ribeiro AB, Kurokawa K, Lash JP, et al. Renal risk and renoprotection among ethnic groups with type 2 diabetic nephropathy: a post hoc analysis of RENAAL. Kidney Int 2006; 69: 1675-1682.
68. Seaquist ER, Goetz FC, Rich S, Barbosa J. Familial clustering of diabetic kidney disease. N Engl J Med 1989; 320: 1161-1165.
69. Thorn LM, Forsblom C, Fagerudd J, Pettersson-Fernholm K, Kilpikari R, Groop PH; FinnDiane Study Group. Clustering of risk factors in parents of patients with type 1 diabetes and nephropathy. Diabetes Care 2007; 30: 1162-1167.
70. Schelling JR, Abboud HE, Nicholas SB, Pahl MV, Sedor JR, Adler SG, et al. Genome-wide scan for estimated glomerular filtration rate in multi-ethnic diabetic populations: the Family Investigation of Nephropathy and Diabetes (FIND). Diabetes 2008; 57: 235-243.
71. Gordin D, Hiilesmaa V, Fagerudd J, Ronnback M, Forsblom C, Kaaja R, et al; FinnDiane Study Group. Pre-eclampsia but not pregnancy -induced hypertension is a risk factor for diabetic nephropathy in type 1 diabetic women. Diabetologia 2007; 50: 516-522.
72. Lopes-Virella MF, Carter RE, Gilbert GE, Klein RL, Jaffa M, Jenkins AJ, et al; Diabetes Control and Complications Trial/Epidemiology of Diabetes Intervention and Complications Cohort Study Group. Risk factors related to inflammation and endothelial dysfunction in the DCCT/EDIC cohort and their relationship with nephropathy and macrovascular complications. Diabetes Care 2008; 31: 2006-2012.
73. Schrijvers BF, de Vriese AS, Flyvbjerg A. From hyperglycemia to diabetic kidney disease: the role of metabolic, hemodynamic and intracellular factors and growth factors/cytokines. Endocrine Rev 2004; 25: 971-1010.
74. Shultis WA, Weil EJ, Looker HC, Curtis JM, Shlossman M, Genco RJ, et al. Effect of periodontitis on overt nephropathy and end-stage renal disease in type 2 diabetes. Diabetes Care 2007; 30: 306-311.
75. Hovind P, Hansen TK, Tarnow L, Steffensen R, Flyvbjerg A, Parving HH. Mannose-binding lectin as a predictor of microalbuminuria in type 1 diabetes: an inception cohort study. Diabetes 2005; 54: 1523-1527.
76. Hansen TK, Gall MA, Tarnow L, Thiel S, Stehouwer CD, Schalkwijk CG, et al. Mannose-binding lectin and mortality in type 2 diabetes. Ann Intern Med 2006; 166: 2007-2013.
77. Jorsal A, Tarnow L, Flyvbjerg A, Parving HH, Rossing P, Rasmussen LM. Plasma osteoprotegerin levels predict cardiovascular and all-cause mortality and deterioration of kidney function in type 1 diabetic patients with nephropathy. Diabetologia 2008; 51: 2100-2107.
78. Targher G, Bertolini L, Rodella S, Zoppini G, Lippi G, Day C, et al. Non-alcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and proliferative/ laser-treated retinopathy in type 2 diabetic patients. Diabetologia 2008; 51: 444-450.
79. Aso Y. Cardiovascular disease in patients with diabetic nephropathy. Curr Mol Med 2008; 8: 533-543.
80. Deckert T, Yokoyama H, Mathiesen E, Rønn B, Jensen T, Feldt-Rasmussen B, et al. Cohort study of predictive value of urinary albumin excretion for atherosclerotic vascular disease in patients with insulin dependent diabetes. Br Med J 1996; 312: 871-874.
81. Rossing P, Houggard P, Borch-Johnsen K, Parving HH. Predictors of mortality in IDDM: 10 year observational follow-up study. Br Med J 1996; 313: 779-784.
82. Borch-Johnsen K, Kreiner S. Proteinuria: value as predictor of cardiovascular mortality in insulin-dependent diabetes mellitus. Br Med J 1989; 294: 1651-1654.
83. Tuomilehto J, Borch-Johnsen K, Molarius A, Forsen T, Rastenyte D, Sarti C, et al. Incidence of cardiovascular disease in type 1 (insulin-dependent) diabetic patients with and without diabetic nephropathy in Finland. Diabetologia 1998; 41: 784-790.
84. Dinneen SF, Gerstein HC. The association of microalbuminuria and mortality in non-insulin-dependent diabetes mellitus: a systematic overview of the literature. Arch Intern Med 1997; 157: 1413-1418.
85. Fuller JH, Stevens LK, Wang SL, WHO Multinational Study Group. Risk factors for cardiovascular mortality and morbidity: the WHO Multinational Study of Vascular Disease in Diabetes. Diabetologia 2001; 44 (Suppl. 2): 54-64.
86. Mann JF, Gerstein HC, Pogue J, Bosch J, Yusef S. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomised trial. Ann Intern Med 2001; 134: 629-636.
87. Adler AI, Stevens RJ, Manley SE, Bilous RW, Cull CA, Holman RR; UKPDS Group. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 2003; 63: 225-232.
88. Nag S, Bilous R, Kelly W, Jones S, Roper N, Connolly V. All-cause and cardiovascular mortality in diabetic subjects increases signifi-cantly with reduced estimated glomerular filtration rate (eGFR): 10 years'data from the South Tees Diabetes Mortality study. Diabet Med 2007; 24: 10-17.
89. McCullough PA, Jurkovitz CT, Pergola PE, McGill JB, Brown WW, Collins AJ, et al. Independent components of chronic kidney disease as a cardiovascular risk state: results from the Kidney Early Evaluation Program (KEEP). Arch Intern Med 2007; 167: 1122-1129.
90. So WY, Kong AP, Ma RC, Ozaki R, Szeto CC, Chan NN, et al. Glomerular filtration rate, cardiorenal end points, and all-cause mortality in type 2 diabetic patients. Diabetes Care 2006; 29: 2046-2052.
91. Bruno G, Merietti F, Bargero G, Novelli G, Melis D, Soddu A, et al. Estimated glomerular filtration rate, albuminuria and mortality in type 2 diabetes: the Casale Monferrato study. Diabetologia 2007; 50: 941-948.
92. Norgaard K, Feldt-Rasmussen B, Borch-Johnsen K, Saelan H, Deckert T. Prevalence of hypertension in type 1 (insulin-dependent) diabetes mellitus. Diabetologia 1990; 33: 407-410.
93. Chase HP, Garg SK, Harris S, Hoops SL, Marshall G. High normal blood pressure and early diabetic nephropathy. Arch Intern Med 1990; 150: 639-641.
94. Poulsen PL, Hansen KW, Mogensen CE. Ambulatory blood pressure in the transition from normo-to microalbuminuria: a longitudinal study in IDDM patients. Diabetes 1994; 43: 1248-1253.
95. Margolis DJ, Hofstad O, Feldman HI. Association between renal failure and foot ulcer or lower-extremity amputation in patients with diabetes. Diabetes Care 2008; 31: 1331-1336.
96. Ko SH, Park SA, Cho JH, Song KH, Yoon KH, Cha BY, et al. Progression of cardiovascular autonomic dysfunction in patients with type 2 diabetes: a 7-year follow-up study. Diabetes Care 2008; 31: 1832-1836.
97. Moran A, Palmas W, Field L, Bhattarai J, Schwartz JE, Weinstock RS, et al. Cardiovascular autonomic neuropathy is associated with microalbuminuria in older patients with type 2 diabetes. Diabetes Care 2004; 27: 972-977.
98. Hallan SI, Ritz E, Lydersen S, Romundstad S, Kvenild K, Orth SR. Combining GFR and albuminuria to classify CKD improves prediction of ESRD. J Am Soc Nephrol 2009; 20: 1069-1077.
99. Levey AS, Coresh J, Greene T; for the Chronic Kidney Disease Epidemiology Collaboration. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomeurlar filtration rate. Ann Intern Med 2006; 145: 247-254.
100. Stevens LA, Coresh J, Feldman HI, Greene T, Lash JP, Nelson RG, et al. Evaluation of the modification of diet in renal disease study equation in a large diverse population. J Am Soc Nephrol 2007; 18: 2749-2757.
101. Basker V, Venugopal H, Holland MR, Singh BM. Clinical utility of estimated glomerular filtration rates in predicting renal risk in a district diabetes population. Diabet Med 2006; 23: 1057-1060.
102. Fontsere N, Bonal J, Salinas I, de Arellano MR, Rios J, Torres F, et al. Is the new Mayo Clinic quadratic equation useful of the estimation of glomerular filtration rate in type 2 diabetic patients? Diabetes Care 2008; 31: 2265-2267.
103. Chudleigh RA, Dunseath G, Evans W, Harvey JN, Evans P, Ollerton R, et al. How reliable is estimation of glomerular filtration rate at diagnosis of type 2 diabetes? Diabetes Care 2007; 30: 300-305.
104. Rossing P, Rossing K, Gæde P, Pedersen O, Parving HH. Monitoring kidney function in type 2 diabetic patients with incipient and overt nephropathy. Diabetes Care 2006; 29: 1024-1030.
105. Beauvieux MC, Le Moigne F, Lasseur C, Raffaitin C, Perlemoine C, Berthe N, et al. New predictive equations improve monitoring of kidney function in patients with diabetes. Diabetes Care 2007; 30: 1988-1994.
106. Tan GD, Lewis AV, James TJ, Altmann P, Taylor RP, Levy JC. Clinical usefulness of cystatin C for the estimation of glomerular filtration rate in type 1 diabetes: reproducibility and accuracy compared with standard measures and iohexol clearance. Diabetes Care 2002; 25: 2000-2004.
107. Perkins BA, Nelson RG, Ostrander BE, Blouch KL, Krolewski AS, Myers BD, et al. Detection of renal function decline in patients with diabetes and normal or elevated GFR by serial measurements of serum cystatin C concentration: results of a 4-year follow-up study. J Am Soc Nephrol 2005; 16: 1404-1412.
108. MacIsaac RJ, Tsalamandris C, Thomas MC, Premaratne E, Panagiotopoulos S, Smith TJ, et al. Estimating glomerular filtration rate in diabetes: a comparison of cystatin C and creatinine-based methods. Diabetologia 2006; 49: 1686-1689.
109. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-986.
110. Diabetes Control and Complications Trial Research Group. The absence of a glycaemic threshold for the development of long-term complications: the prospective of the Diabetes Control and Complications Trial. Diabetes 1996; 45: 1289-1298.
111. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med 2000; 342: 381-389.
112. Writing Team for the Diabetes Control and Complications Trial/ Epidemiology of Diabetes Interventions and Complications Research Group. Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy. Epidemiology of Diabetes Interventions and Complications (EDIC) Study. JAMA 2003; 290: 2159-2167.
113. EUCLID Study Group. Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. Lancet 1997; 349: 1787-1792.
114. Bilous RW, Chaturvedi N, Sjølie AK, Fuller J, Klein R, Orchard T, et al. Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomised trials. Ann Intern Med 2009; 151: 11-20.
115. UK Prospective Diabetes Study. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet 1998; 352: 837-853.
116. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. Br Med J 2000; 321: 405-412.
117. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359: 1577-1589.
118. ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358: 2560-2572.
119. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes (UKPDS 38). Br Med J 1998; 317: 703-713.
120. Adler AI, Stratton IM, Neil HA, Yudkin JS, Matthews DR, Cull CA, et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes: prospective observational study (UKPDS 36). Br Med J 2000; 321: 412-419.
121. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes (UKPDS 39). Br Med J 1998; 317: 713-720.
122. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000; 355: 253-259.
123. Patel A; ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007; 370: 829-840.
124. Strippoli GF, Craig M, Schena FP, Craig JC. Antihypertensive agents for primary prevention of diabetic nephropathy. J Am Soc Nephrol 2005; 16: 3081-3091.
125. Holman RR, Paul SK, Bethel MA, Neil HA, Matthews DR. Long-term follow-up after tight control of blood pressure in type 2 diabetes. N Engl J Med 2008; 359: 1565-1576.
126. Bending JJ, Viberti GC, Watkins PJ, Keen H. Intermittent clinical proteinuria and renal function in diabetes: evolution and the effect of glycaemic control. Br Med J 1986; 292: 83-86.
127. Feldt-Rasmussen B, Mathiesen ER, Deckert T. Effect of two years of strict metabolic control on progression of incipient nephropathy in insulin-dependent diabetes. Lancet 1986; ii: 1300-1304.
128. Feldt-Rasmussen B, Mathiesen ER, Hegedus L, Deckert T. Kidney function during 12 months of strict metabolic control in insulin-dependent diabetic patients with incipient nephropathy. N Engl J Med 1986; 314: 665-670.
129. Fioretto P, Steffes MW, Sutherland DE, Goetz FC, Mauer M. Reversal of lesions of diabetic nephropathy after pancreas transplantation. N Engl J Med 1998; 339: 115-117.
130. ACE Inhibitors in Diabetic Nephropathy Trialist Group. Should all patients with type 1 diabetes mellitus and microalbuminuria receive angiotensin-converting enzyme inhibitors? A meta-analysis of individual patient data. Ann Intern Med 2001; 134: 370-379.
131. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin -converting enzyme inhibition on diabetic nephropathy. N Engl J Med 1993; 329: 1456-1462.
132. Andersen S, Tarnow L, Rossing P, Hansen BV, Parving HH. Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy. Kidney Int 2000; 57: 601-606.
133. Kasiske BL, Kalil RSN, Ma JZ, Liao M, Keane WF. Effect of antihypertensive therapy on the kidney in patients with diabetes: a meta-regression analysis. Ann Intern Med 1993; 118: 129-138.
134. Remuzzi G. A unifying hypothesis for renal scarring linking protein trafficking to the different mediators of injury. Nephrol Dial Transplant 2000; 15 (Suppl. 6): 58-60.
135. Zatz R, Dunn BR, Meyer TW, Brenner B. Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. J Clin Lab Invest 1986; 77: 1925-1930.
136. European Study for the Prevention of Renal Disease in Type 1 Diabetic Patients (ESPRIT) Research Group. Effect of 3 years antihypertensive therapy on renal structure in type 1 diabetic patients with albuminuria. Diabetes 2001; 50: 843-580.
137. Hovind P, Rossing P, Tarnow L, Smidt UM, Parving HH. Progression of diabetic nephropathy. Kidney Int 2001; 59: 702-709.
138. Parving HH, Hommel E, Jensen BR, Hansen HP. Long-term benefi-cial effect of ACE inhibition on diabetic nephropathy in normotensive type 1 diabetic patients. Kidney Int 2001; 60: 228-324.
139. Hovind P, Rossing P, Tarnow L, Smidt UM, Parving HH. Remission and regression in the nephropathy of type 1 diabetes when blood pressure is controlled aggressively. Kidney Int 2001; 60: 277-283.
140. Jacobsen P, Andersen S, Rossing K, Jensen BR, Parving HH. Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy. Kidney Int 2003; 63: 1874-1880.
141. Jacobsen P, Andersen S, Jensen BR, Parving HH. Additive effect of ACE inhibition and angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy. Kidney Int 2003; 63: 1874-1880.
142. MacKinnon M, Shurraw S, Akbari A, Knoll GA, Jaffey J, Clark HD. Combination therapy with an angiotensin receptor blocker and an ACE inhibitor in proteinuric renal disease: a systematic review of the efficacy and safety data. Am J Kidney Dis 2006; 48: 8-20.
143. Schødt KJ, Rossing K, Juhl TR, Boomsma F, Rossing P, Tarnow L, et al. Beneficial impact of spironolactone in diabetic nephropathy. Kidney Int 2005; 68: 2829-2836.
144. Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes: a randomised prospective 6-year study. Diabetes Res Clin Pract 1995; 28: 103-117.
145. Shichiri M, Kishikawa H, Ohkubo Y, Wake N. Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. Diabetes Care 2000; 23 (Suppl 2): B21-29.
146. Sano T, Hotta N, Kawamura T, Matsumae H, Chaya S, Sasaki H, et al. Effects of long-term enalapril treatment on persistent microalbuminuria in normotensive type 2 diabetic patients: results of a 4-year, prospective, randomised study. Diabet Med 1996; 13: 120-124.
147. Ravid M, Savin H, Jutrin I, Bental T, Katz B, Lishner M. Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann Intern Med 1993; 118: 577-581.
148. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-869.
149. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851-860.
150. Barnett AH, Bain SC, Bouter P, Karlberg B, Madsbad S, Jervell J, et al. Angiotensin-receptor blockade versus converting enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med 2004; 351: 1952-1961.
151. Lacourciere Y, Belanger A, Godin C, Halle JP, Ross S, Wright N, et al. Long-term comparison of losartan and enalapril on kidney function in hypertensive type 2 diabetics with early nephropathy. Kidney Int 2000; 58: 762-769.
152. Mogensen CE, Neldam S, Tikkanen I, Oren S, Viskoper R, Watts RW, et al. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. Br Med J 2000; 321: 1440-1444.
153. Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK; AVOID Study Investigators. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 2008; 358: 2433-2446.
154. Ustundag A, Tugrul A, Ustundag S, Sut N, Demirkan B. The effects of spironolactone on nephrin function in patients with diabetic nephropathy. Ren Fail 2008; 30: 982-991.
155. Swaminathan K, Davies J, George J, Rajendra NS, Morris AD, Struthers AD. Spironolactone for poorly controlled hypertension in type 2 diabetes: conflicting effects on blood pressure, endothelial function, glycemic control and hormonal profiles. Diabetologia 2008; 51: 762-768.
156. Mann JF, Schmieder RE, McQueen M, Dyal L, Schumacher H, Poque J, et al. Renal outcomes with telmisartan, ramipril, or both, in people at high risk (the ONTARGET study): a multi-centre, randomized, double-blind, controlled trial. Lancet 2008; 372: 547-553.
157. Robertson L, Waugh N, Robertson A. Protein restriction for diabetic renal disease. Cochrane Database Syst Rev 2007; 17: CD002181.
158. Gæde P, Vedel P, Parving HH, Pedersen O. Intensive multifactorial intervention in patients with type 2 diabetes and microalbuminuria (the Steno 2 Study). Lancet 1999; 353: 617-622.
159. Gæde P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003; 348: 383-393.
160. Gæde P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008; 358: 580-591.
161. Ng JM, Jennings PE, Laboi P, Jayagopal V. Erythropoietin treatment significantly alters measured glycated haemoglobin (HbA1c). Diabet Med 2008; 25: 239-242.
162. New JP, Aung T, Baker PG, Yongsheng G, Pylypczuk R, Houghton J, et al. The high prevalence of unrecognized anaemia in patients with diabetes and chronic kidney disease: a population-based study. Diabet Med 2008; 25: 564-567.
163. Jayapaul MK, Messersmith R, Bennett-Jones DN, Mead PA, Large DM. The joint diabetes-renal clinic in clinical practice: 10 years of data from a district general hospital. Q J Med 2006; 99: 153-160.
164. Howarth C, Gazis A, James D. Association of type 1 diabetes mellitus, maternal vascular disease and complications of pregnancy. Diabet Med 2007; 24: 1229-1234.
165. Haeri S, Khoury J, Kovilam O, Miodovnik M. The association of intrauterine growth abnormalities in women with type 1 diabetes mellitus complicated by vasculopathy. Am J Obstet Gynecol 2008; 199: 278e1-5.
166. Cooper WO, Hernandez-Diaz S, Arboqast PG, Dudley JA, Dyer S, Gideon PS, et al. Major congenital malformations after first trimester exposure to ACE inhibitors. N Engl J Med 2006; 354: 2443-2451.
167. Nielsen LR, Damm P, Mathiesen ER. Improved pregnancy outcome in type 1 diabetic women with microalbuminuria or diabetic nephropathy: effect of intensified antihypertensive therapy? Diabetes Care 2009; 32: 38-44.